Abstract
The management of primary and secondary malignancies of the peritoneum continues to pose a challenge to modern, multidisciplinary cancer care.[...]
Highlights
The management of primary and secondary malignancies of the peritoneum continues to pose a challenge to modern, multidisciplinary cancer care
■ For stage iii primary epithelial ovarian or fallopian tube carcinoma, or primary peritoneal carcinoma, hipec should be considered after neoadjuvant chemotherapy at the time of interval crs if optimal cytoreduction is achieved
In Europe, clinical and patient equipoise have been lacking for more than 25 years with respect to the role of systemic therapy alone compared with crs with or without intraperitoneal therapy plus systemic therapy for resectable carcinomatosis of colorectal and appendiceal origin[5]
Summary
The management of primary and secondary malignancies of the peritoneum continues to pose a challenge to modern, multidisciplinary cancer care. ■ For rare tumours, including malignant peritoneal mesothelioma and disseminated mucinous neoplasm of the appendix, the evidence is insufficient to recommend hipec with crs as the standard of care, but patients should be referred to hipec specialty centres for assessment as part of an ongoing research protocol.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
